Exploring the role of an organization in implementing a Work-From-Home Strategy

Organizations are trying to move quickly to adopt remote working policies into their organizations as to attract and retain top talent, reduce office space costs, and increase productivity. As many of these strategies were quickly adopted by South African ICT organizations during the COIVD-19 pandemic, organizations are still somewhat unclear on what their role is with regards to ensuring long term adoption of remote working. Thus, this study explored the role of the organization with regards to a work-from-home strategy. It was found that the organization is responsible for formalizing the chosen strategy, creating supportive policies, and adapting its management styles to facilitate remote working

Developing a model to assess Feasible Capacity to Work-From-Home

With the growing popularity of Work-From-Home (WFH) organizations have been required to adapt their ‘ways of working’ strategies to the ‘new normal’, as both employees and organizations aim to reap the benefits of WFH. This has resulted in organizations and their leadership teams needing to create WFH strategies for their organizations. With many of these WFH strategies developed in isolation of all stakeholders, with the feasibility of these WFH strategies remain uncertain. Therefore, this research task has reviewed literature to develop a conceptual model that describes how leadership teams can make informed feasible WFH strategy decisions, through the concept of a Theoretical Capacity to WFH. The proposed model describes the WFH Domain and how the WFH Domain influences the Feasible Capacity to implement a feasible WFH strategy. Thus, indicating to leadership how to form a feasible WFH strategy for their organization

Coordination chemistry and biology of chelators for the treatment of iron overload disorders

Treatment of the medical condition generally referred to as iron overload through the delivery of chelators has recently received a major boost. In 2005 Novartis gained FDA approval for the drug deferasirox, which may be taken orally. Until this time most patients with Fe overload have had to endure long periods of subcutaneous infusions of the orally ineffective drug desferrioxamine (desferal) which has led to major problems with patient compliance. An effective Fe chelator must possess a number of properties for it to be able to complex Fe in vivo and be excreted intact. This Perspective will provide an overview of the current state of chelators for Fe overload; both those currently approved and those undergoing preclinical development

2-DPMP (desoxypipradrol, 2-benzhydrylpiperidine, 2-phenylmethylpiperidine) and D2PM (diphenyl-2-pyrrolidin-2-yl-methanol, diphenylprolinol) : A preliminary review

Copyright 2012 Elsevier B.V., All rights reserved.2-DPMP (desoxypipradrol, 2-benzhydrylpiperidine, 2-phenylmethylpiperidine) and D2PM (diphenyl-2-pyrrolidin-2-yl-methanol, diphenylprolinol) are psychoactive substances, sold primarily over the Internet and in 'head' shops as 'legal highs', 'research chemicals' or 'plant food'. Originally developed in the 1950s for the treatment of narcolepsy and ADHD, 2-DPMP's use soon became very limited. Recreational use of 2-DPMP and D2PM appears to have started in March 2007, but only developed slowly. However, in the UK their popularity grew in 2009, increasing rapidly during summer 2010. At this time, there were many presentations to UK Emergency Departments by patients complaining of undesirable physical and psychiatric effects after taking 2-DPMP. In spring 2011 there were similar presentations for D2PM. Recreational use of these drugs has been reported only occasionally in on-line user fora. There is little scientifically-based literature on the pharmacological, physiological, psychopharmacological, toxicological and epidemiological characteristics of these drugs. Here we describe what is known about them, especially on their toxicity, including what we believe to be the first three deaths involving the use of 2-DPMP in August 2010. There are no international controls imposed on 2-DPMP or D2PM. However, a ban on their UK importation was imposed in November 2011 and they became Class C drugs on 13 June 2012. It is critical that any other cases, including non-fatal overdoses, are documented so that a scientific evidence-base can be established for them.Peer reviewedSubmitted Versio